Oliveto Joseph 4

What Happened

• Joseph Oliveto, President, CEO and a director of Milestone Pharmaceuticals (MIST), reported multiple transactions: a performance stock unit (PSU) award tied to FDA approval, conversions/exercises of derivative awards, and open-market sales to cover taxes. Key moves: a 280,000-PSU award reported 2025-12-12, sell-to-cover sales of 133,054 shares on 2025-12-15 for a weighted average $2.32 (proceeds $308,685), conversion/exercise of 66,600 derivative shares on 2026-01-26, and sale of 34,523 shares on 2026-01-26 at $1.93 (proceeds $66,629). Total disclosed sale proceeds ≈ $375,314; award/conversion entries show $0 exercise price for the derivative grants.

Key Details

• Transaction dates & prices:
  • 2025-12-12: 280,000 PSUs awarded (no cash paid; contingent award).
  • 2025-12-15: 133,054 shares sold (sell-to-cover) at weighted avg $2.32; proceeds $308,685. (F4: weighted average price; multiple sale prices included.)
  • 2026-01-26: 66,600 derivative shares converted/exercised (no cash amount shown).
  • 2026-01-26: 34,523 shares sold at $1.93; proceeds $66,629.
• Shares owned after these transactions: not disclosed in the provided filing excerpt.
• Notable footnotes:
  • F1–F2: The 280,000 award are PSUs that vest upon FDA approval of Cardamyst (etripamil); each PSU converts to one common share if conditions met.
  • F3: The December and January sales were sell-to-cover transactions to satisfy income tax withholding on vested PSUs/RSUs.
  • F7: The RSU award vests in quarterly/annual tranches (1/4th on Jan 26 each year 2026–2029).
  • F4: Reported sale price for Dec. 15 is a weighted average across multiple trades; detailed per-trade prices available on request.
• Filing timing: The Form 4 was filed on 2026-01-28 and covers transactions from 2025-12-12 through 2026-01-26. The December transactions appear to have been reported several weeks after the trade date, which may indicate a late reporting of those earlier transactions.

Context

• These filings show awards (PSUs/RSUs) converting to shares and partial sales that are described as sell-to-cover for tax obligations — a common administrative step and not necessarily a signal about sentiment on the company’s prospects.
• The derivative conversion (M code) indicates the conversion/exercise of equity awards (RSUs/PSUs) rather than an open-market purchase. Some of the shares issued on vesting were immediately sold to cover taxes rather than retained.